 Ana Gleisner
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 21 | 2023 | 734 | 3.910 |
Why?
| | Sentinel Lymph Node | 8 | 2022 | 40 | 3.110 |
Why?
| | Adenocarcinoma | 20 | 2023 | 812 | 2.830 |
Why?
| | Liver Neoplasms | 21 | 2024 | 527 | 2.820 |
Why?
| | Melanoma | 11 | 2022 | 664 | 2.690 |
Why?
| | Laparoscopy | 8 | 2021 | 417 | 2.650 |
Why?
| | Skin Neoplasms | 11 | 2022 | 762 | 2.560 |
Why?
| | Pancreaticoduodenectomy | 10 | 2021 | 128 | 2.460 |
Why?
| | Carcinoma, Hepatocellular | 9 | 2024 | 227 | 2.110 |
Why?
| | Lymph Node Excision | 10 | 2023 | 158 | 2.070 |
Why?
| | Pancreatectomy | 6 | 2023 | 165 | 1.970 |
Why?
| | Sentinel Lymph Node Biopsy | 11 | 2023 | 118 | 1.690 |
Why?
| | Hepatectomy | 17 | 2024 | 139 | 1.610 |
Why?
| | Minimally Invasive Surgical Procedures | 5 | 2020 | 158 | 1.410 |
Why?
| | Postoperative Complications | 11 | 2023 | 2235 | 1.260 |
Why?
| | Esophagectomy | 4 | 2021 | 110 | 1.030 |
Why?
| | Liver Transplantation | 10 | 2023 | 847 | 1.030 |
Why?
| | Lymph Nodes | 7 | 2023 | 455 | 1.010 |
Why?
| | Robotic Surgical Procedures | 3 | 2019 | 89 | 0.960 |
Why?
| | Esophageal Neoplasms | 7 | 2023 | 281 | 0.950 |
Why?
| | Retrospective Studies | 50 | 2024 | 12978 | 0.920 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 13 | 0.920 |
Why?
| | Nomograms | 2 | 2022 | 48 | 0.900 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2023 | 210 | 0.880 |
Why?
| | Breast Neoplasms | 4 | 2023 | 1965 | 0.820 |
Why?
| | Survival Rate | 22 | 2023 | 1720 | 0.820 |
Why?
| | Rectal Neoplasms | 5 | 2023 | 121 | 0.820 |
Why?
| | Lymphatic Metastasis | 10 | 2023 | 307 | 0.810 |
Why?
| | Prognosis | 24 | 2024 | 3443 | 0.750 |
Why?
| | Aged | 44 | 2023 | 19657 | 0.680 |
Why?
| | Quality of Life | 2 | 2019 | 2366 | 0.660 |
Why?
| | Neoplasm Recurrence, Local | 10 | 2023 | 900 | 0.630 |
Why?
| | Middle Aged | 53 | 2023 | 27617 | 0.630 |
Why?
| | Head and Neck Neoplasms | 6 | 2019 | 471 | 0.600 |
Why?
| | Humans | 90 | 2024 | 118972 | 0.600 |
Why?
| | Colorectal Neoplasms | 7 | 2017 | 628 | 0.580 |
Why?
| | Neoadjuvant Therapy | 11 | 2023 | 333 | 0.580 |
Why?
| | Colectomy | 3 | 2013 | 84 | 0.540 |
Why?
| | Female | 63 | 2023 | 61564 | 0.520 |
Why?
| | Neoplasm Staging | 9 | 2023 | 1223 | 0.510 |
Why?
| | Liver Failure | 3 | 2009 | 85 | 0.510 |
Why?
| | Male | 59 | 2023 | 57801 | 0.470 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 224 | 0.470 |
Why?
| | Axilla | 3 | 2023 | 57 | 0.460 |
Why?
| | Risk Assessment | 5 | 2019 | 3057 | 0.460 |
Why?
| | Decision Making | 1 | 2019 | 809 | 0.440 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4596 | 0.440 |
Why?
| | Treatment Outcome | 19 | 2023 | 9342 | 0.410 |
Why?
| | Databases, Factual | 6 | 2019 | 1231 | 0.360 |
Why?
| | Neuroendocrine Tumors | 2 | 2023 | 83 | 0.350 |
Why?
| | Benchmarking | 2 | 2021 | 172 | 0.340 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 10 | 0.340 |
Why?
| | Metastasectomy | 2 | 2023 | 12 | 0.340 |
Why?
| | Aged, 80 and over | 15 | 2021 | 6561 | 0.330 |
Why?
| | Peritoneal Neoplasms | 2 | 2020 | 53 | 0.330 |
Why?
| | Margins of Excision | 4 | 2023 | 31 | 0.320 |
Why?
| | Propensity Score | 2 | 2019 | 242 | 0.320 |
Why?
| | Length of Stay | 4 | 2019 | 1032 | 0.310 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 91 | 0.300 |
Why?
| | Disease-Free Survival | 8 | 2024 | 649 | 0.290 |
Why?
| | Catheter Ablation | 2 | 2008 | 286 | 0.280 |
Why?
| | Hyperglycemia | 2 | 2020 | 312 | 0.260 |
Why?
| | Adult | 28 | 2022 | 31512 | 0.250 |
Why?
| | Abdomen, Acute | 1 | 2004 | 20 | 0.250 |
Why?
| | Cohort Studies | 10 | 2023 | 5116 | 0.250 |
Why?
| | Lymphopenia | 1 | 2024 | 48 | 0.240 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 245 | 0.240 |
Why?
| | Bacterial Infections | 3 | 2006 | 227 | 0.240 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 12 | 0.230 |
Why?
| | SEER Program | 2 | 2014 | 205 | 0.230 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 8 | 0.220 |
Why?
| | Survival Analysis | 6 | 2017 | 1267 | 0.220 |
Why?
| | Mastectomy | 1 | 2023 | 124 | 0.220 |
Why?
| | Pelvic Exenteration | 2 | 2019 | 12 | 0.210 |
Why?
| | Klatskin Tumor | 1 | 2021 | 4 | 0.210 |
Why?
| | United States | 13 | 2023 | 12555 | 0.210 |
Why?
| | Anesthetics, Inhalation | 1 | 2021 | 14 | 0.200 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 40 | 0.200 |
Why?
| | Bile Duct Neoplasms | 1 | 2021 | 55 | 0.200 |
Why?
| | Propofol | 1 | 2021 | 49 | 0.190 |
Why?
| | Prospective Studies | 8 | 2022 | 6471 | 0.190 |
Why?
| | Hyperthermia, Induced | 2 | 2020 | 67 | 0.190 |
Why?
| | Organ Preservation | 4 | 2023 | 67 | 0.190 |
Why?
| | Chemoradiotherapy | 4 | 2023 | 200 | 0.190 |
Why?
| | Odds Ratio | 3 | 2019 | 996 | 0.180 |
Why?
| | Registries | 2 | 2021 | 1810 | 0.180 |
Why?
| | Combined Modality Therapy | 5 | 2019 | 1166 | 0.180 |
Why?
| | Reoperation | 3 | 2017 | 557 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2023 | 360 | 0.180 |
Why?
| | Scalp | 1 | 2019 | 29 | 0.180 |
Why?
| | Anesthesia | 1 | 2021 | 120 | 0.180 |
Why?
| | Pancreatic Diseases | 1 | 2019 | 63 | 0.170 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.170 |
Why?
| | Skin Pigmentation | 1 | 2019 | 43 | 0.170 |
Why?
| | Population Surveillance | 1 | 2021 | 413 | 0.160 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 14 | 0.160 |
Why?
| | Tumor Burden | 3 | 2023 | 274 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 252 | 0.150 |
Why?
| | Patient Compliance | 1 | 2021 | 537 | 0.150 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 23 | 0.150 |
Why?
| | Ampulla of Vater | 1 | 2017 | 28 | 0.150 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 7 | 0.150 |
Why?
| | Waiting Lists | 2 | 2009 | 228 | 0.150 |
Why?
| | Pylorus | 1 | 2017 | 13 | 0.150 |
Why?
| | Disease Management | 1 | 2021 | 571 | 0.150 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 128 | 0.150 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 91 | 0.150 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 42 | 0.150 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 35 | 0.140 |
Why?
| | Nutritional Status | 1 | 2019 | 300 | 0.140 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 72 | 0.140 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 31 | 0.140 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 42 | 0.140 |
Why?
| | Cannabis | 1 | 2023 | 382 | 0.140 |
Why?
| | Hospitals | 1 | 2021 | 598 | 0.140 |
Why?
| | Time Factors | 4 | 2021 | 6412 | 0.140 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 105 | 0.130 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1125 | 0.130 |
Why?
| | Adenoma | 1 | 2017 | 191 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2436 | 0.130 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1510 | 0.130 |
Why?
| | Radiosurgery | 1 | 2018 | 318 | 0.120 |
Why?
| | Lung Neoplasms | 2 | 2023 | 2220 | 0.120 |
Why?
| | Patient Readmission | 1 | 2019 | 634 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 2 | 2013 | 842 | 0.120 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 1974 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2021 | 867 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 1390 | 0.120 |
Why?
| | Morbidity | 4 | 2021 | 296 | 0.120 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 45 | 0.120 |
Why?
| | Trauma Centers | 2 | 2014 | 388 | 0.120 |
Why?
| | Abdomen | 1 | 2013 | 110 | 0.110 |
Why?
| | Radiation Dosage | 1 | 2014 | 147 | 0.110 |
Why?
| | Clinical Competence | 1 | 2019 | 951 | 0.110 |
Why?
| | Renal Insufficiency | 1 | 2013 | 150 | 0.100 |
Why?
| | Risk Factors | 5 | 2019 | 9000 | 0.100 |
Why?
| | Asia | 2 | 2021 | 54 | 0.100 |
Why?
| | Triage | 1 | 2012 | 203 | 0.090 |
Why?
| | Age Factors | 4 | 2022 | 2995 | 0.090 |
Why?
| | Carcinoma, Renal Cell | 1 | 2012 | 174 | 0.090 |
Why?
| | Europe | 2 | 2021 | 356 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1440 | 0.090 |
Why?
| | Kidney Transplantation | 2 | 2013 | 585 | 0.090 |
Why?
| | Organ Preservation Solutions | 2 | 2006 | 44 | 0.090 |
Why?
| | Graft Survival | 2 | 2009 | 504 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1200 | 0.080 |
Why?
| | Brain Injuries | 1 | 2014 | 484 | 0.080 |
Why?
| | Laparotomy | 1 | 2008 | 106 | 0.080 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2008 | 28 | 0.080 |
Why?
| | Young Adult | 7 | 2022 | 10793 | 0.080 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 334 | 0.080 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2008 | 27 | 0.080 |
Why?
| | Gallbladder Neoplasms | 1 | 2007 | 11 | 0.080 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 462 | 0.080 |
Why?
| | Intraoperative Care | 1 | 2007 | 39 | 0.080 |
Why?
| | Anus Neoplasms | 1 | 2007 | 24 | 0.080 |
Why?
| | Electrocoagulation | 1 | 2007 | 36 | 0.080 |
Why?
| | Cholangitis, Sclerosing | 1 | 2008 | 75 | 0.080 |
Why?
| | Neoplasms | 1 | 2021 | 2179 | 0.070 |
Why?
| | Congenital Hypothyroidism | 1 | 1986 | 12 | 0.070 |
Why?
| | Hospital Mortality | 3 | 2019 | 814 | 0.070 |
Why?
| | Fluorouracil | 2 | 2022 | 151 | 0.070 |
Why?
| | Ultrasonography, Interventional | 1 | 2007 | 155 | 0.070 |
Why?
| | Mycophenolic Acid | 1 | 2006 | 79 | 0.070 |
Why?
| | Adolescent | 9 | 2022 | 18480 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2012 | 772 | 0.060 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2674 | 0.060 |
Why?
| | Zygomycosis | 1 | 2003 | 6 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 189 | 0.060 |
Why?
| | alpha-Fetoproteins | 1 | 2023 | 33 | 0.060 |
Why?
| | Developmental Disabilities | 1 | 1986 | 247 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1527 | 0.060 |
Why?
| | Antibiotic Prophylaxis | 1 | 2004 | 100 | 0.060 |
Why?
| | Hepatocytes | 1 | 2004 | 205 | 0.060 |
Why?
| | Appendicitis | 1 | 2004 | 125 | 0.050 |
Why?
| | Inflammation | 2 | 2023 | 2566 | 0.050 |
Why?
| | Biology | 1 | 2023 | 83 | 0.050 |
Why?
| | Capecitabine | 1 | 2022 | 46 | 0.050 |
Why?
| | CA-19-9 Antigen | 1 | 2022 | 14 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 610 | 0.050 |
Why?
| | Anesthesia, Intravenous | 1 | 2021 | 12 | 0.050 |
Why?
| | Surgical Wound Infection | 1 | 2004 | 251 | 0.050 |
Why?
| | Anesthetics, Intravenous | 1 | 2021 | 34 | 0.050 |
Why?
| | Esophagogastric Junction | 1 | 2021 | 41 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 59 | 0.050 |
Why?
| | Liver | 2 | 2006 | 1816 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1715 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2020 | 58 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2007 | 3171 | 0.050 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2020 | 59 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 34 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 110 | 0.040 |
Why?
| | Perioperative Period | 1 | 2017 | 51 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2004 | 1178 | 0.040 |
Why?
| | Operative Time | 1 | 2017 | 114 | 0.040 |
Why?
| | Parotid Gland | 1 | 2017 | 25 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 56 | 0.040 |
Why?
| | Occipital Bone | 1 | 2017 | 20 | 0.040 |
Why?
| | ROC Curve | 2 | 2009 | 473 | 0.040 |
Why?
| | Obesity | 1 | 2010 | 2746 | 0.040 |
Why?
| | Gastric Emptying | 1 | 2017 | 40 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 132 | 0.040 |
Why?
| | Neck | 1 | 2017 | 89 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 1781 | 0.040 |
Why?
| | Raffinose | 2 | 2006 | 20 | 0.030 |
Why?
| | Preoperative Care | 2 | 2008 | 332 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1355 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 534 | 0.030 |
Why?
| | Allopurinol | 2 | 2006 | 82 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 953 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 295 | 0.030 |
Why?
| | Glutathione | 2 | 2006 | 324 | 0.030 |
Why?
| | Adenosine | 2 | 2006 | 211 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 736 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 150 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 523 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2014 | 88 | 0.030 |
Why?
| | Child | 6 | 2014 | 19129 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2490 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2424 | 0.030 |
Why?
| | Vital Signs | 1 | 2012 | 42 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2014 | 131 | 0.030 |
Why?
| | New South Wales | 1 | 2012 | 10 | 0.030 |
Why?
| | Child, Preschool | 4 | 2014 | 9491 | 0.030 |
Why?
| | Baltimore | 1 | 2012 | 42 | 0.030 |
Why?
| | Italy | 1 | 2012 | 90 | 0.030 |
Why?
| | Hospital Costs | 1 | 2012 | 110 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 167 | 0.030 |
Why?
| | Biological Therapy | 1 | 2011 | 26 | 0.030 |
Why?
| | Albuminuria | 1 | 1992 | 195 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 525 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3664 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 528 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2013 | 683 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1474 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2014 | 5255 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 681 | 0.020 |
Why?
| | Carcinoembryonic Antigen | 1 | 2008 | 36 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 83 | 0.020 |
Why?
| | Infant | 3 | 2014 | 8293 | 0.020 |
Why?
| | Brazil | 1 | 2008 | 109 | 0.020 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2008 | 131 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1795 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4196 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 194 | 0.020 |
Why?
| | Cholecystectomy | 1 | 2007 | 45 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 71 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 103 | 0.020 |
Why?
| | Incidental Findings | 1 | 2007 | 80 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2008 | 298 | 0.020 |
Why?
| | Hepatitis B | 1 | 2007 | 52 | 0.020 |
Why?
| | Tablets, Enteric-Coated | 1 | 2006 | 4 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 190 | 0.020 |
Why?
| | Histidine | 1 | 2006 | 63 | 0.020 |
Why?
| | Psychological Tests | 1 | 1986 | 129 | 0.020 |
Why?
| | Overweight | 1 | 2010 | 502 | 0.020 |
Why?
| | Radiography | 1 | 2008 | 861 | 0.020 |
Why?
| | Tryptophan | 1 | 2006 | 139 | 0.020 |
Why?
| | Graft Rejection | 1 | 2009 | 555 | 0.020 |
Why?
| | Insulin | 2 | 2006 | 2162 | 0.020 |
Why?
| | Glutathione Disulfide | 1 | 2004 | 29 | 0.020 |
Why?
| | Hepatitis C | 1 | 2007 | 217 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2006 | 187 | 0.020 |
Why?
| | Sulfamethoxypyridazine | 1 | 1983 | 1 | 0.020 |
Why?
| | Trimethoprim | 1 | 1983 | 6 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2004 | 107 | 0.010 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 1983 | 14 | 0.010 |
Why?
| | Amphotericin B | 1 | 2003 | 31 | 0.010 |
Why?
| | Liver Diseases | 1 | 2006 | 282 | 0.010 |
Why?
| | Patient Selection | 1 | 2007 | 676 | 0.010 |
Why?
| | Antifungal Agents | 1 | 2003 | 134 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 2092 | 0.010 |
Why?
| | Urinary Tract Infections | 1 | 1983 | 136 | 0.010 |
Why?
| | Cause of Death | 1 | 2004 | 380 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2003 | 200 | 0.010 |
Why?
| | Reperfusion Injury | 1 | 2004 | 276 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 1992 | 1798 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1992 | 3360 | 0.010 |
Why?
| | Cholesterol | 1 | 1992 | 373 | 0.010 |
Why?
| | Blood Pressure | 1 | 1992 | 1664 | 0.000 |
Why?
| | Sulfamethoxazole | 1 | 1983 | 6 | 0.000 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1983 | 37 | 0.000 |
Why?
| | Escherichia coli Infections | 1 | 1983 | 105 | 0.000 |
Why?
| | Drug Combinations | 1 | 1983 | 291 | 0.000 |
Why?
| | Microbial Sensitivity Tests | 1 | 1983 | 302 | 0.000 |
Why?
| | Cross-Sectional Studies | 1 | 1992 | 4552 | 0.000 |
Why?
| | Escherichia coli | 1 | 1983 | 758 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1983 | 969 | 0.000 |
Why?
|
|
Gleisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|